This study looked at men with high-risk prostate cancer that returned after initial treatment. It was a randomized controlled trial comparing enzalutamide alone against leuprolide alone. The research followed patients for five years to see how long they lived and how the cancer behaved over time.
Results showed enzalutamide was associated with higher survival rates and less cancer spread to other parts of the body. Patients taking enzalutamide also stayed free from symptoms longer and had better sexual health scores. The chance of needing more hormone therapy was lower with enzalutamide compared to leuprolide.
Important details are missing from this report. The total number of patients and specific safety side effects were not shared. Because this is only an abstract, we do not have full information on how well the drugs were tolerated or if there were serious issues.
These findings suggest enzalutamide might be a strong option for this specific group. Still, doctors need to weigh the benefits against unknown safety data. Patients should discuss these results with their care team before making changes to their treatment plan.